|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2006-6-26
|
|
pubmed:abstractText |
The aim of the study was to assess whether loss of PTEN and expression of insulin-like growth factor receptor 1 (IGFR-1) could be responsible for intrinsic resistance to the tyrosine kinase inhibitor (TKI) gefitinib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BartoliniSS,
pubmed-author:BunnP APAJr,
pubmed-author:CancellieriAA,
pubmed-author:CappuzzoFF,
pubmed-author:CeresoliG LGL,
pubmed-author:CrinoLL,
pubmed-author:DomenichiniII,
pubmed-author:FinocchiaroGG,
pubmed-author:FranklinW AWA,
pubmed-author:HirschF RFR,
pubmed-author:MagriniEE,
pubmed-author:MetriMM,
pubmed-author:SantoroAA,
pubmed-author:TalliniGG,
pubmed-author:ToschiLL,
pubmed-author:TrisoliniRR,
pubmed-author:Varella-GarciaMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1120-7
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16600976-Adult,
pubmed-meshheading:16600976-Aged,
pubmed-meshheading:16600976-Aged, 80 and over,
pubmed-meshheading:16600976-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16600976-Drug Resistance,
pubmed-meshheading:16600976-Female,
pubmed-meshheading:16600976-Humans,
pubmed-meshheading:16600976-Lung Neoplasms,
pubmed-meshheading:16600976-Male,
pubmed-meshheading:16600976-Middle Aged,
pubmed-meshheading:16600976-Multivariate Analysis,
pubmed-meshheading:16600976-PTEN Phosphohydrolase,
pubmed-meshheading:16600976-Patient Selection,
pubmed-meshheading:16600976-Protein Kinase Inhibitors,
pubmed-meshheading:16600976-Quinazolines,
pubmed-meshheading:16600976-Receptor, IGF Type 1,
pubmed-meshheading:16600976-Survival Analysis,
pubmed-meshheading:16600976-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
|
|
pubmed:affiliation |
University of Colorado Cancer Center, Department of Medicine/Medical Oncology and Pathology, Aurora, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
